Welcome to our dedicated page for AGIOS PHARMACEUTICALS SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Agios Pharmaceuticals, Inc. filings document the regulatory record of a Delaware, Nasdaq-listed commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its 8-K reports furnish operating results, product revenue updates for PYRUKYND® and AQVESME™, business highlights, investor presentations, and Regulation FD disclosures tied to mitapivat commercialization, clinical programs, and regulatory interactions.
Proxy and current-report filings cover annual-meeting proposals, director elections, board-class structure, committee assignments, stockholder voting matters, and compensatory arrangements for directors. Other disclosures address board appointments, pharmacovigilance communications involving PYRUKYND, exhibit filings, and Inline XBRL cover-page data.
AGIOS PHARMACEUTICALS Chief Medical Officer Sarah Gheuens reported equity compensation activity involving restricted and performance share units. On June 18, 2026, she received a grant of 3,000 restricted stock units, each representing a contingent right to one share of common stock. The same day, she also acquired 3,000 shares of common stock through the exercise or conversion of 3,000 performance share units, with each unit likewise tied to one common share. These performance share units were originally granted on March 1, 2025 and vest based on three specified clinical and research milestones set by the board and its compensation and people committee. The performance criteria for one research milestone was determined to be met as of June 18, 2026, and the related shares are scheduled to vest on December 31, 2027, subject to Dr. Gheuens’s continued service. Following these transactions, she holds 3,000 restricted stock units and 9,000 performance share units, and the filing shows only acquisitions with no sales or tax-withholding dispositions.
Jones Cecilia reported acquisition or exercise transactions in this Form 4 filing.
AGIOS PHARMACEUTICALS, INC. Chief Financial Officer Cecilia Jones reported equity compensation activity involving restricted stock units and performance share units. She received a grant of 3,000 restricted stock units, each representing a contingent right to one share of common stock. A separate award of 3,000 performance share units tied to a specified research milestone had its performance criteria determined to be met as of June 18, 2026. The underlying shares for this milestone are scheduled to vest on December 31, 2027, subject to her continued service.
AGIOS PHARMACEUTICALS, INC. Chief Commercial Officer Tsveta Milanova reported equity-based compensation changes involving restricted and performance share units tied to common stock. She received 3,000 restricted stock units, each representing a contingent right to one share of common stock, bringing her holdings in that award type to 3,000 units.
She also acquired 3,000 shares through the exercise of performance share units, increasing her total directly held common stock from these derivative transactions to 9,000 shares. The performance stock units were originally granted on March 1, 2025 and vest based on three specified clinical and research milestones. The performance criteria for a specified research milestone were determined to be met as of June 18, 2026, and the related shares are scheduled to vest on December 31, 2027, subject to her continued service.
AGIOS PHARMACEUTICALS, INC. director Jay T. Backstrom received new equity awards as part of his compensation. He was granted stock options for 14,950 shares of common stock at an exercise price of $34.16 per share, vesting in full on June 18, 2027 and expiring on June 18, 2036.
He also received 2,927 restricted stock units, each representing a contingent right to one share of common stock. These RSUs vest in full on June 18, 2027, with shares to be delivered within three business days after vesting. These are routine awards, not open-market purchases or sales.
Agios Pharmaceuticals, Inc. reported that stockholders approved an amendment to its 2023 Stock Incentive Plan at the 2026 annual meeting. The amendment increases the number of shares of common stock available for issuance under the plan by 2,000,000 shares and raises the limit for incentive stock options by the same amount.
Stockholders also elected directors, including Rahul Ballal, Ph.D., Brian Goff and Cynthia Smith, and approved additional proposals, with support levels reflected in detailed vote tallies such as 48,511,213 votes for one item versus 116,938 against and 15,376 abstaining.
AGIOS PHARMACEUTICALS director Catherine Owen Adams exercised restricted stock units into common stock. She converted 1,976 restricted stock units into 1,976 shares of common stock at a stated price of $0.00 per share and did not sell any shares. Following the transaction, she directly holds 8,049 shares of common stock. The restricted stock units were granted on June 13, 2023 and vest in three equal annual installments beginning on June 13, 2024, with vested shares delivered within three business days after vesting.
AGIOS PHARMACEUTICALS, INC. director Jeffrey D. Capello reported the vesting and conversion of previously granted restricted stock units into common shares. On June 13, 2026, he exercised 1,976 restricted stock units into 1,976 shares of common stock at a stated price of $0.00 per share, reflecting a compensation-related equity award rather than an open-market purchase. These units were part of a grant made on June 13, 2023, scheduled to vest in three equal annual installments beginning June 13, 2024. After this transaction, Capello directly holds 8,049 shares of Agios common stock.
Agios Pharmaceuticals ownership filing shows Armistice Capital, LLC and Steven Boyd report beneficial ownership of 2,716,000 shares of common stock, representing 4.57% of the class. The filing states Armistice Capital exercises shared voting and dispositive power over those shares under an Investment Management Agreement.
The filing explains the Master Fund is the direct holder and that Mr. Boyd, as managing member of Armistice Capital, may be deemed to beneficially own the securities held by the Master Fund. Signatures are dated May 15, 2026.
Agios Pharmaceuticals ownership update: Lynx1 Capital Management and Weston Nichols report beneficial ownership of 3,013,949 shares of Agios common stock, representing 5.1% of the class. The percentage is calculated using 59,471,609 shares outstanding as of April 24, 2026.
The filing states the shares are held by Lynx1 Master Fund LP with shared voting and dispositive power, and the statement is a joint filing by the Investment Manager and Mr. Nichols.
Agios Pharmaceuticals Inc: Vanguard Capital Management reports beneficial ownership of 3,088,169 shares of Agios common stock, representing 5.27% of the class as of 03/31/2026. Vanguard reports sole dispositive power over the 3,088,169 shares and sole voting power over 455,853 shares. The filing states these holdings reflect positions managed by Vanguard Capital Management LLC and specified affiliates, including shares held by Vanguard funds and managed accounts.